▁by ▁ce ph ale x in ). ▁In ▁addition , ▁or it av anc in ▁showed ▁a ▁significantly ▁improved ▁safety ▁profile ▁with ▁a ▁ 1 9 . 2 ▁percent ▁relative ▁reduction ▁in ▁the ▁overall ▁inc idence ▁of ▁ad verse ▁events ▁versus ▁van com yc in / ce ph ale x in ▁( p < 0 . 0 0 1 ) ▁in ▁the ▁second ▁and ▁larger ▁p iv otal ▁trial . ▁ ▁T arg anta ▁also ▁developed ▁a ▁novel ▁drug ▁discovery ▁platform ▁to ▁generate ▁mole cules ▁that ▁deliver ▁ant ib iot ics ▁directly ▁to ▁the ▁b one . ▁ ▁Also ▁at ▁the ▁ 4 7 th ▁I CA AC ▁meeting ▁in ▁September ▁ 2 0 0 7 , ▁T arg anta ▁presented ▁the ▁first ▁in ▁v ivo ▁pre - cl in ical ▁data ▁on ▁candidates ▁from ▁this ▁program , ▁demonstr ating ▁effic acy ▁of ▁its ▁rif ab ut in - bis ph os phon ate ▁prod rug ▁( TT 9 9 0 0 0 6 4 7 ) ▁in ▁a ▁rabb it ▁o ste omy el itis ▁model . ▁ ▁References ▁ ▁Category : Bi ote chn ology ▁companies ▁of ▁the ▁United ▁States ▁Category : E li ▁L illy ▁and ▁Company ▁Category : Comp an ies ▁formerly ▁listed ▁on ▁NAS DA Q ▁Category : Ph arma ce ut ical ▁companies ▁established ▁in ▁ 1 9 9 7 ▁Category : Comp an ies ▁dis est ab lished ▁in ▁ 2 0 0 9 ▁Category : Comp an ies ▁based ▁in ▁Cambridge , ▁Massachusetts <0x0A> </s>